Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

Documenti analoghi

• Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
  di: Salmon, J H, et al.
  Pubblicazione: (2015)
• Lack of efficacy of rituximab in Felty's syndrome
  di: Sordet, C, et al.
  Pubblicazione: (2005)
• Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
  di: Gottenberg, Jacques-Eric, et al.
  Pubblicazione: (2019)
• Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome
  di: Seror, Raphaèle, et al.
  Pubblicazione: (2007)
• Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
  di: Juge, Pierre-Antoine, et al.
  Pubblicazione: (2017)